DIFFERENTIAL ALTERATIONS OF CYTOCHROME-P450 PROTEINS IN LIVERS FROM PATIENTS WITH SEVERE CHRONIC LIVER-DISEASE

被引:49
作者
GEORGE, J
MURRAY, M
BYTH, K
FARRELL, GC
机构
[1] UNIV SYDNEY,WESTMEAD HOSP,DEPT GASTROENTEROL & HEPATOL,STORR LIVER UNIT,WESTMEAD,NSW 2145,AUSTRALIA
[2] UNIV SYDNEY,WESTMEAD HOSP,DEPT MED,WESTMEAD,NSW 2145,AUSTRALIA
关键词
D O I
10.1002/hep.1840210121
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
To determine whether cytochrome P450 proteins were differentially altered in severe chronic liver diseases, we examined 50 livers removed at liver transplantation from patients with end-stage cirrhosis, including 18 with and 32 without cholestasis, and compared the results with 21 histologically normal livers. NADPH-cytochrome c reductase activities were unaltered in microsomes from cirrhotic Livers. Total cytochrome P450 content was significantly reduced. The catalytic activities of four xenobiotic-metabolizing P450s and the level of the corresponding proteins were differentially altered. Thus, P450 3A-supported testosterone 6 beta-hydroxylase activity and 3A protein appeared to be reduced, but only in the subgroup without cholestasis was this change significant. In contrast, 2E1 and the related N,N-dimethylnitrosamine N-demethylase activity were clearly reduced in livers from patients with cholestatic forms of cirrhosis but appeared not to be changed in other cirrhotic livers. Similarly, P450 2C protein was reduced only in patients with severe chronic cholestasis. Finally, P450 1A2 and 1A2-supported ethoxyresorufin O-deethylase activity were significantly reduced in hepatic microsomes from patients with both types of advanced Liver disease. In summary, these data demonstrate that cytochrome P450 proteins are selectively altered in severe chronic liver disease, some being profoundly decreased, others less so dr not at all. Our results also suggest that there may be different patterns of altered hepatic P450 expression according to the presence or absence of cholestasis in patients with cirrhosis severe enough to require transplantation.
引用
收藏
页码:120 / 128
页数:9
相关论文
共 46 条
  • [1] INVITRO INHIBITION STUDIES OF TOLBUTAMIDE HYDROXYLASE-ACTIVITY OF HUMAN-LIVER MICROSOMES BY AZOLES, SULFONAMIDES AND QUINOLINES
    BACK, DJ
    TJIA, JF
    KARBWANG, J
    COLBERT, J
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 26 (01) : 23 - 29
  • [2] MONO-OXYGENASE ACTIVITY OF HUMAN-LIVER IN MICROSOMAL FRACTIONS OF NEEDLE-BIOPSY SPECIMENS
    BOOBIS, AR
    BRODIE, MJ
    KAHN, GC
    FLETCHER, DR
    SAUNDERS, JH
    DAVIES, DS
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1980, 9 (01) : 11 - 19
  • [3] DETERMINANTS OF SERUM ANTIPYRINE HALF-LIVES IN PATIENTS WITH LIVER-DISEASE
    BRANCH, RA
    HERBERT, CM
    READ, AE
    [J]. GUT, 1973, 14 (07) : 569 - 573
  • [4] BUTLER MA, 1989, CANCER RES, V49, P25
  • [5] COMBALBERT J, 1989, DRUG METAB DISPOS, V17, P197
  • [6] DISTLERATH LM, 1985, J BIOL CHEM, V260, P9057
  • [7] PHARMACOKINETICS OF NIFEDIPINE AFTER ORAL-ADMINISTRATION IN CHRONIC LIVER-DISEASE
    ENE, MD
    ROBERTS, CJC
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (12) : 1001 - 1004
  • [8] DRUG-METABOLISM IN LIVER-DISEASE - ACTIVITY OF HEPATIC MICROSOMAL METABOLIZING ENZYMES
    FARRELL, GC
    COOKSLEY, WGE
    POWELL, LW
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1979, 26 (04) : 483 - 492
  • [9] FARRELL GC, 1983, GASTROENTEROLOGY, V85, P275
  • [10] ROLE OF HUMAN HEPATIC CYTOCHROMES-P450 IN DRUG-METABOLISM AND TOXICITY
    GEORGE, J
    FARRELL, GC
    [J]. AUSTRALIAN AND NEW ZEALAND JOURNAL OF MEDICINE, 1991, 21 (03): : 356 - 362